<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004300</url>
  </required_header>
  <id_info>
    <org_study_id>199/11754</org_study_id>
    <secondary_id>UF-63394</secondary_id>
    <nct_id>NCT00004300</nct_id>
  </id_info>
  <brief_title>Phase II Study of Stereotypes and Mental Retardation: Neurobiological Basis</brief_title>
  <official_title>Phase II Study of Stereotypes and Mental Retardation: Neurobiological Basis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Office of Rare Diseases (ORD)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Determine differences between persons with repetitive behavior disorders and&#xD;
      matched controls on measures of motor control relevant to basal ganglia pathophysiology.&#xD;
&#xD;
      II. Determine the efficacy of bromocriptine, a dopamine agonist, in the treatment of&#xD;
      stereotyped behavior and related behavior disorders.&#xD;
&#xD;
      III. Determine the efficacy of sertraline hydrochloride, a selective serotonin uptake&#xD;
      inhibitor, in the treatment of repetitive behavior disorders.&#xD;
&#xD;
      IV. Identify behavioral, environmental, and biological variables with differential drug&#xD;
      treatment response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: Motor slowness (bradykinesia) and motor control are tested in repetitive&#xD;
      behavior disorder patients and matched controls. Group differences reflecting alterations in&#xD;
      basal ganglia dopamine function are compared.&#xD;
&#xD;
      Behavioral assessments are conducted on each patient by trained observers. Assessments are&#xD;
      taken at baseline and during the maintenance phase of drug treatment described below.&#xD;
&#xD;
      The efficacy of bromocriptine in the treatment of stereotypy and self-injury is determined in&#xD;
      a randomized, double blind, placebo controlled, crossover study extending over 20 weeks.&#xD;
      Cohorts of 6 to 8 patients first enter into a single blind placebo phase, followed by double&#xD;
      blind treatment with placebo or bromocriptine. The crossover manipulation entails a titration&#xD;
      phase, a maintenance phase, then a final single blind placebo condition.&#xD;
&#xD;
      The same experimental design is used to determine the efficacy of sertraline or placebo in&#xD;
      the treatment of stereotypy and concomitant self injury and compulsions. Duration of study is&#xD;
      26 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>40</enrollment>
  <condition>Stereotyped Behavior</condition>
  <condition>Mental Retardation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bromocriptine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sertraline hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
          -  Diagnosis of mental retardation&#xD;
&#xD;
          -  High rate of stereotyped behavior, such as concomitant self-injurious and compulsive&#xD;
             behaviors&#xD;
&#xD;
          -  No diagnosis of tardive dyskinesia or akathisia&#xD;
&#xD;
        --Prior/Concurrent Therapy--&#xD;
&#xD;
          -  No exposure to neuroleptics within 6 months prior to study&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
          -  Age: 18 to 55&#xD;
&#xD;
          -  Hematopoietic: (for bromocriptine and sertraline treatments) No history of anemia No&#xD;
             clinically significant hematologic disease&#xD;
&#xD;
          -  Hepatic: (for bromocriptine and sertraline treatments) No history of hepatic&#xD;
             abnormalities No clinically significant liver disease&#xD;
&#xD;
          -  Renal: (for bromocriptine and sertraline treatments) No history of renal abnormalities&#xD;
             No clinically significant renal disease&#xD;
&#xD;
          -  Cardiovascular: (for bromocriptine and sertraline treatments) No history of&#xD;
             hypertension No clinically significant cardiac disease&#xD;
&#xD;
          -  Other: No history of seizure within 4 months prior to study (for bromocriptine and&#xD;
             sertraline treatments) No history of sensitivity to ergot alkaloids (for bromocriptine&#xD;
             treatment) No sensitivity to serotonin uptake inhibitors (for sertraline treatment) No&#xD;
             patients with sensory deficits (for motor function assessments)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark H. Lewis</last_name>
    <role>Study Chair</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Western Carolina Center</name>
      <address>
        <city>Morganton</city>
        <state>North Carolina</state>
        <zip>28655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2006</verification_date>
  <study_first_submitted>October 18, 1999</study_first_submitted>
  <study_first_submitted_qc>October 18, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 1999</study_first_posted>
  <last_update_submitted>October 5, 2010</last_update_submitted>
  <last_update_submitted_qc>October 5, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2010</last_update_posted>
  <responsible_party>
    <name_title>Mark Lewis</name_title>
    <organization>University of Florida</organization>
  </responsible_party>
  <keyword>mental retardation</keyword>
  <keyword>neurologic and psychiatric disorders</keyword>
  <keyword>rare disease</keyword>
  <keyword>stereotyped behavior</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intellectual Disability</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromocriptine</mesh_term>
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

